

Evaluation of the Level of Satisfaction of Patients with the Use of a Newly Marketed Vaginal Gel (Satisvag Survey)

Santiago Palacios¹, Fernando Losa², Josep Combalia³, Carine Emsellem³, Yann Gaslain³ and Danial Khorsandi^{3,4,5*}

¹Palacios Institute of Women's Health and Medicine, Madrid, Spain

²Sagrada Familia Clinic, Barcelona, Spain

³Procure Health Iberia, Castelldefels, Barcelona, Spain

⁴University of Barcelona, Barcelona, Spain

⁵Harvard-MIT's Division of Health Science and Technology, MA, USA

*Corresponding author: Danial Khorsandi, Universitat de Barcelona, Pharmacy and Pharmaceutical Technology, Campus Diagonal, Av. de Joan XXIII, 27-3 Barcelona Spain, Tel: +34617772262; E-mail: danialkhorsandi92@gmail.com

Received date: March 15, 2018; Accepted date: March 24, 2018; Published date: March 28, 2018

Copyright: © 2018 Palacios S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective: To evaluate the general level of satisfaction of the patients in relation to the use of Palomacare®, a multi-ingredient, non-hormonal vaginal gel with moisturizing and restorative properties indicated for the improvement of symptoms and signs that make up the genitourinary syndrome, after its recent commercialization.

Methods: The satisvag survey was addressed during the first quarter of 2016 to Spanish Gynaecologists who were visiting women that already were using Palomacare®. At the end, collected data were analyzed.

Results: A total of 62 doctors participated in the survey, ~ 90% of them had ≥ 5 patients using Palomacare®. 98% of survey respondents indicated the overall satisfaction with Palomacare® in their patients is good or excellent. On the other hand, 84% of them stated that patients considered the product better or much better than previous treatments, respectively.

Conclusion: After analyzing the data we assured that Palomacare® is a well-tolerated product with a comfortable application. Its specific features make the product use highly satisfactory and perceived as better than other previous treatments.

Introduction

For any product that is administered vaginally, both the comfort of application and the sensations of the patient are key factors to determine overall satisfaction. This has a direct impact on the adherence and, ultimately, the effectiveness of the prescribed treatment. Quickly understanding the advantages and disadvantages of a newly marketed product, could be useful to improve prescription habits and patient response [1-5].

Palomacare® is a multi-ingredient including Niosome and Phytosome particles, which contains Hyaluronic Acid and natural ingredients. This medical device marketed in Spain since July 2015 [6-9]. Vaginally applied in the form of a gel with moisturizing and restorative properties of the vaginal mucosa, it is indicated for improvement of symptoms and signs that make up the genitourinary syndrome.

The objective of this survey was to determine the opinion of doctors in relation to the overall satisfaction of patients with the use of Palomacare®, after its recent commercialization [10,11].

Methods

The Satisvag survey was conducted during the first quarter of 2016. A questionnaire of eight questions was performed related to the use of

Palomacare® in clinical practice. The survey was targeted to Spanish gynecologists already prescribing Palomacare® to their patients and followed a homogeneous distribution across the country. Data quality was ensured through double-entry Microsoft Excel®.

Results

A total of 62 doctors participated in the survey, having the ~ 90% of them ≥5 patients using Palomacare®. 98% of survey respondents indicated the overall satisfaction with Palomacare® in their patients is good or excellent (Q2). Data concerning to both general comfort and general comparison to other products (Q3 and Q5) are shown in Figure 1.




Figure 1: Results to Q3 and Q5.

95% indicated that absorption, understood as the absence of product loss, is good or excellent (Q4). The main advantages of Palomacare® highlighted by users, especially compared to previous products are shown in Figure 2 (Q6). Nearly 90% of doctors said that no patient reported any adverse effect (Q7). Stinging/burning was indicated as the most common adverse effect observed.




Figure 2: Are your patients highlighting some advantage of Palomacare® especially compared to previous products used?

Discussion

Palomacare® is a well-tolerated product with a comfortable application. Its specific features make the product use highly satisfactory and perceived as better than other previous treatments.

References

1. Palacios S, Losa F, Combalia J, Emsellem C, Gaslain Y, et al. (2018) Evaluation of the Benefits of a Newly Marketed Vaginal Gel (Palomacare®) on Vaginal Health of Peri and Postmenopausal Women (Atrovag Survey). *EC Gynaecology* 7: 104-106.
2. Karaosmanoglu O (2011) Hyaluronic acid in the treatment of postmenopausal women with atrophic vaginitis. *Int J Gynaecol Obstet* 113: 156-157.
3. Brochure Nio-Glucan. Naturalis life technologies (Italy).
4. Lu L (2004) Asiatic acid induction for cell-cycle progression proliferation and collagen synthesis in human dermal fibroblasts. *Int J Dermatol* 43: 801-807.
5. Lee JH, Kim HL, Lee MH, You KE, Kwon BJ, et al. (2012) Asiaticoside enhances normal human skin cell migration, attachment, and growth in vitro wound healing model. *Phytomedicine*.
6. Hashim P (2014) The effect of Centella Asiatica, vitamins, glycolic acid and their mixtures preparation in stimulating collagen and fibronectin synthesis in cultured human skin fibroblast. *Pak J Pharm Sci* 27: 233-237.
7. Brochure Bioecolia (2013) Via Farma. Iparanga Brazil.
8. Molazem Z, Mohseni F, Younesi M, Keshavarzi S (2014) Aloe vera gel, and cesarean wound healing: a randomized controlled clinical trial. *Global J Health Sci* 31: 203-209.
9. Khan AW, Kotta S, Ansari SH, Sharma RK, Kumar A, et al. (2013) Formulation development, optimization and evaluation of aloe vera gel for wound healing. *Pharmacogn Mag* 9 (Suppl 1): S6-S10.
10. Chu K, Ho SS, Chow AH (2002) Coriolus versicolor: a medicinal mushroom with promising immunotherapeutic values. *Journal of Clinical Pharmacology* 42: 976-984.
11. Palacios S, Losa F, Dexeus D, Cortés J (2017) Beneficial effects of a Coriolus versicolor based vaginal gel on cervical epithelization, vaginal microbiota, and vaginal health: a pilot study in asymptomatic women. *BMC Women's Health* 17: 21.